back to US directory
us clinical guidance

Major depressive disorder assessment and treatment

VA/DoD-aligned adult depression assessment, shared treatment selection, measurement-based follow-up and urgent risk escalation.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with possible or established major depressive disorder in primary or specialty care. The 2022 VA/DoD guideline informs assessment and stepped treatment but does not replace local emergency procedures, product labeling or specialist management of bipolar disorder, psychotic depression, catatonia, pregnancy, postpartum illness or pediatric depression.
sources for this section:VA/DoD MDD 2022

The Bottom Line

  • Confirm a depressive syndrome from symptoms, duration, distress and functional impairment; a positive questionnaire supports assessment but does not establish the diagnosis by itself.
  • Assess suicide risk, self-harm, mania or hypomania, psychosis, substance use, trauma, medical contributors and prior treatment before selecting therapy.
  • Use shared decision-making to offer an evidence-based psychotherapy, pharmacotherapy or their combination according to severity, complexity, prior response, access and patient preference.
  • Track symptoms, function, adherence and adverse effects with a consistent measure and revise the plan when an adequate treatment trial has not produced meaningful improvement.
sources for this section:VA/DoD MDD 2022

Practical clinical workflow

1
Elicit mood, anhedonia, sleep, appetite, energy, concentration, guilt, psychomotor change, thoughts of death, episode history, impairment and protective factors in the patient鈥檚 own context.
2
Review bipolar and psychotic symptoms, alcohol and drugs, medications, bereavement, chronic pain, sleep disorder and medical illness; order targeted tests only when history or examination supports them.
3
Agree on goals and start a guideline-supported psychotherapy or appropriately selected antidepressant, explaining expected time course, early adverse effects, adherence and how to seek help.
4
Arrange proactive follow-up, reassess with the same symptom and function measures, optimize an incomplete trial and obtain specialty input for treatment resistance, diagnostic uncertainty or complex comorbidity.
sources for this section:VA/DoD MDD 2022

Safety boundaries and escalation

  • Current intent, plan, preparatory behavior, inability to maintain safety or rapidly escalating suicidal thinking requires immediate risk management, not routine outpatient scheduling; use 911 or 988 pathways as appropriate.
  • Mania, psychosis, catatonia, severe self-neglect, inability to eat or drink or marked agitation needs urgent psychiatric or emergency evaluation and changes the treatment strategy.
  • Monitor for activation, worsening suicidal thinking, serotonin toxicity, bleeding, hyponatremia, sexual adverse effects and discontinuation symptoms according to the chosen medicine and patient risk.
  • Do not stop long-term psychiatric medication abruptly or infer that lack of response proves the diagnosis; revisit adherence, dose, duration, comorbidity, bipolarity and psychosocial barriers.
sources for this section:VA/DoD MDD 2022VA/DoD suicide risk 2024

Localization

VA/DoD provides a current US federal evidence framework, but community psychotherapy networks, state crisis systems, formularies and prior authorization differ. Call or text 988 for the US Suicide & Crisis Lifeline when clinically appropriate.
sources for this section:VA/DoD MDD 2022

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. U.S. Department of Veterans Affairs and U.S. Department of Defense Evidence-Based Practice Work GroupVA/DoD Clinical Practice Guideline for the Management of Major Depressive DisorderVersion 4.0 (2022); official guideline page checked 2026-08-20 路 accessed 2026-08-20
    view source
  2. U.S. Department of Veterans Affairs and U.S. Department of Defense Evidence-Based Practice Work GroupVA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide2024 guideline; official guideline page checked 2026-08-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.